

## Recent scientific publications on lipolysis (Courtesy of network lipodissolve)

- **Hasenschwandtner F.** Injection Lipolysis for Effective Reduction of Localized Fat in Place of Minor Surgical Lipoplasty, *Aesthetic Surgery Journal* 2006;26:125-130
- **Hasenschwandtner F.:** Phosphatidylcholine treatment to induce lipolysis, *JCD*, Vol.4, 4; 308-313, Dec.2005
- **Hasenschwandtner F.** Die subc.Injektion von Phosphatidylcholin zum Zwecke der Lipolyse, *Akt.Dermatol* 2005;31:549-552
- **Duncan D., Hasenschwandtner F.** Lipodissolve for Subcutaneous Fat Reduction and Skin Retraction *Aesthetic Surg J* 2005; 25:530-543.
- Rose P.T., Morgan M. Histological changes associated with mesotherapy for fat dissolution *J of Cosmetic and Laser Therapy*. 2005;7:17-19
- Rotunda A. Lipomas treated with subc.deoxycholate inj. *J.Am Acad Dermatol*,53(6):973-8, dec2005
- Hexsel D. et al Cosmetic Use of Injectable Phosphatidylcholine on the Face, *Otolaryngol Clin N Am* 38 (2005) 1119-1129
- **Hasenschwandtner F.** The non surgical liposculpture *J.of Cosm.Dermatology*, 4-2005, 310-315
- Ablon G, Rotunda AM. Treatment of lower eyelid fat pads using phosphatidylcholine: clinical trial and review. *Dermatol Surg* 2004;30: 422-7.
- Rittes PG. The use of phosphatidylcholine for correction of localized fat deposits. *Aesthetic Plast Surg* 2003;27: 315-8.
- Hexsel D, Serra M, Mazzuco R, Dal'Forno T, Zechmeister D. Phosphatidylcholine in the treatment of localized fat. *J Drugs Dermatol* 2003;2: 511-8.
- Young VL. Lipostabil: the effect of phosphatidylcholine on subcutaneous fat. *Aesthet Surg J* 2003;23: 413-7.
- Bellman B. Phosphatidylcholine reaction. *Skin Allergy News* 2003;34: 12.
- Victor S. Phosphatidylcholine works. *Skin Allergy News* 2003;34: 12.
- Bauman LS. Phosphatidylcholine. *Skin Allergy News* 2003; 34: 24.
- Bates B. 'Fat dissolving' substance injects CCs of controversy. *Skin Allergy News* 2003;34: 1.
- American Society for Aesthetic Plastic Surgery. Lipoplasty (Liposuction) Without Surgery? (Internet). New York: The American Society for Aesthetic Plastic Surgery, October, 2002. Available from: [surgery.org/press/news-release.php](http://surgery.org/press/news-release.php).
- Rittes PG. The use of phosphatidylcholine for correction of lower lid bulging due to prominent fat pads. *Dermatol Surg* 2001;27: 391-2.

### Further Publications and references:

---

1. Parnham MJ, Wendel A. Phospholipids and liposomes - safety for cosmetical and pharmaceutical use. Nattermann Phospholipid GMBH Scientific Publication no. 1995432003, 2. Cologne, West Germany: Nattermann International GMBH.

Dazugehörige Referenzen:

Bergenstahl, B. (1990). Phase diagrams of mixed soybean phospholipids. In: *Food Polymers, Gels and Colloids*, edited by E. Dickinson, Royal Society of Chemistry, London, pp. 123-131.

De Vleeschauwer, D., Van der Meeren, P. & Vanderdeelen, J. (1996). Influence of electrolytes on phospholipid-stabilised emulsions. *Bulletins des Societes Chimiques Belges*, 105, 809-814.

De Vleeschauwer, D. & Van der Meeren, P. (1999). Colloid chemical stability and interfacial properties of mixed phospholipid-nonionic surfactant stabilised oil-in-water emulsions. *Colloids and Surfaces A* 152, 59-66.

- Friberg, S.E. & Solans, C. (1986). Surfactant association structures and the stability of emulsions and foams. *Langmuir*, 2, 121-126.
- Hofman, J.A.M.H. & Stein, H.N. (1991). Destabilization of emulsions through deformation of the droplets. *J. Colloid Interface Sci.* 147, 508-516.
- Kaufmann, P., Olsson, O. & Herslof, B.G. (1990). A chemometric strategy for the classification of lecithins according to process performance. *J. Am. Oil Chem. Soc.* 67, 537-540.
- Pardun, H. (1989). Vegetable lecithins - valuable auxiliary and active substances? *Fat Sci. Technol.* 91, 45-58.
- Rydtag, L. (1979). The importance of the phase behaviour of phospholipids for emulsion stability. *Fette, Seifen, Anstrichmittel* 81, 168-173.
- Rydtag, L. & Wilton, I. (1981). The function of phospholipids of soybean lecithin in emulsions. *J. Am. Oil Chem. Soc.* 58, 830-837.
- Szuhaj, B.F. (1989). Lecithins : sources, manufacture & uses, The American Oil Chemists' Society, Champaign, Illinois, 283 p.
- Van der Meeren, P., Stastny, M., Vanderdeelen, J. & Baert, L. (1995a). Functional properties of purified soybean lecithins in O/W emulsions. In: G. Cevc and F. Paltauf (Eds.). *Phospholipids : characterisation, metabolism and novel biological applications*. AOCS Press, Champaign, USA, p.111-119.
- Van der Meeren, P., Vanderdeelen, J. & Baert, L. (1995b). On the relationship between dynamic interfacial tension and O/W emulsion stabilizing properties of soybean lecithins. *Progr. Colloid Polym. Sci.* 98, 136-139.
- Van Nieuwenhuyzen, W. (1997). Functionality of lecithins. *Fett/Lipid*, 99, 10-14.

Internet: [www.dainet.de/fnr/ctvo/newuse/second\\_workshop/7-pap-paul-meeren.doc](http://www.dainet.de/fnr/ctvo/newuse/second_workshop/7-pap-paul-meeren.doc)

2. Lipostabil (package insert). Frankfurt: Aventis Pharma, 2003.
3. Essentiale (package insert). Frankfurt: Aventis Pharma, 2003.
4. How do lecithins work? Learn about lecithins (Internet). Oxford (CT): American Lecithin Company, 2003. Available from: [www.americanlecithin.com/lecithin.pdf](http://www.americanlecithin.com/lecithin.pdf)
5. Lipostabil. Natterman International GMBH. Cologne, Germany: Natterman International, 1990: 9.
6. Durr M, Hager J, Lohr JP. Investigation on mixed micelle and liposome preparations for parental use on soya phosphatidylcholine. *Eur J Pharm Biopharm* 1994;40: 147-56.
7. Lichtenberg D, Zilberman Y, Greenzaid P, Zamir S. Structural and kinetic studies on the solubilization of lecithin by sodium deoxycholate. *Biochemistry* 1979;18: 3517-25.
8. Lichtenberg D, Robson RJ, Dennis EA. Solubilization of phospholipids by detergents: structural and kinetic aspects. *Biochim Biophys Acta* 1983;737: 285-304.
9. Teelmann K, Schlappi B, Schubach M, Kistler A. Preclinical safety evaluation of intravenously administered mixed micelles. *Arzneimittelforschung* 1984;34: 1517-23.
10. Hammad MA, Muller BW. Increasing drug solubility by means of bile salt-phosphatidylcholine-based mixed micelles. *Eur J Pharm Biopharm* 1998;46: 361-7.
11. Alkan-Onyuksel H, Ramakrishnan S, Chai HB, Pezzuto JM. A mixed micellar formulation suitable for the parenteral administration of Taxol. *Pharm Res* 1994, 2003;11: 206-12.
12. Basic Phlebology Primer (Internet). Oakland (CA): American College of Phlebology, c1998. Available from: [www.phlebology.org/topics.htm](http://www.phlebology.org/topics.htm)
13. Vlahcevic ZR, Heuman DM. Diseases of the gall bladder and bile ducts. In: Goldman L, Bennet JC, Cecil R, eds. *Cecil Textbook of Medicine*. St. Louis (MO): Saunders, 2001: 822-4.
14. Womack MD, Kendall DA, MacDonald RC. Detergent effects on enzyme activity and solubilization of lipid bilayer membranes. *Biochim Biophys Acta* 1983;733: 210-5.

15. Lichtenberg D. Characterization of the solubilization of lipid bilayers by surfactants. *Biochim Biophys Acta* 1985;821: 470-8.
16. Banerjee P, Joo JB, Buse JT, Dawson G. Differential solubilization of lipids along with membrane proteins by different classes of detergents. *Chem Phys Lipids* 1995;77: 65-78
17. Almgren M. Mixed micelles and other structures in the solubilization of bilayer lipid membranes by surfactants. *Biochim Biophys Acta* 2000;1508: 146-63.
18. Schuck S, Honsho M, Ekroos K, Shevchenko A, Simons K. Resistance of cell membranes to different detergents. *Proc Natl Acad Sci USA* 2003;100: 5795-800.
19. Heerklotz H, Seelig J. Correlation of membrane/water partition coefficients of detergents with the critical micelle concentration. *Biophys J* 2000;78: 2435-40.
20. Canty D, Zeisel S, Jolitz A. Lecithin and Choline: Research Update on Health and Nutrition. Fort Wayne (IN): Central Soya Company, 1996.
21. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. *Gastroenterology* 1994;106: 152-9.
22. Lieber CS, DeCarli LM. Animal models of chronic ethanol toxicity. *Methods Enzymol* 1994;233: 585-94.
23. Buko V, Lukivskaya O, Nikitin V, et al. Hepatic and pancreatic effects of polyenoylphosphatidylcholine in rats with alloxan-induced diabetes. *Cell Biochem Funct* 1996;14: 131-7.
24. Jones MN. Surfactants in membrane solubilisation. *Int J Pharm* 1999;177: 137-59.
25. Gustafson C, Tagesson C. Influence of organic solvent mixtures on biological membranes. *Br J Ind Med* 1985;42: 591-5.
26. Lester DS, Baumann D. Action of organic solvents on protein kinase C. *Eur J Pharmacol* 1991;206: 301-8.
27. Engelke M, Jessel R, Wiechmann A, Diehl HA. Effect of inhalation anaesthetics on the phase behaviour, permeability and order of phosphatidylcholine bilayers. *Biophys Chem* 1997;67: 127-38.
28. Ebihara L, Hall JE, MacDonald RC, McIntosh TJ, Simon SA. Effect of benzyl alcohol on lipid bilayers: a comparison of bilayer systems. *Biophys J* 1979;28: 185-96.
29. Gordon LM, Sauerheber RD, Esgate JA, et al. The increase in bilayer fluidity of rat liver plasma membranes achieved by the local anesthetic benzyl alcohol affects the activity of intrinsic membrane enzymes. *J Biol Chem* 1980;255: 4519-27.
30. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. *Science* 1972;175: 720-31.
31. Christie, W.W. : *Lipid Analysis – 3. Auflage* ( Oily Press, Bridgewater 2003 )
- 42 . Vance, D.E. and Vance J. : *Biochemistry of Lipids, Lipoproteids and Membranes* ( Elsevier, Amsterdam -2004 )
43. Veldhuizen R., Nag K., Orgeig S, Possmeayer F.: The role of Lipids in pulmonary surfactant (*Biochim. Biophys. Acta* 1408. 90-108 (1998)
44. Xu Y., Spingosynphosphorylcholine and lysophosphatidylcholine, G-protein-coupled receptors and receptor-mediated signal transduction. (*Biochim. Biophys. Acta* 1582, 81-88 2004)
45. Kidd, PM.: *Dietary phospholipids as anti-aging nutraceuticals*
46. Klatz RA, Goldman R, eds. *Anti Aging Medical Therapeutics*, Chicago, Health Quest Publications 2000:283-301 47.
47. NY: Marcel Dekker; 1997:15-30, Kent C.: Eukaryotic phospholipids biosynthesis. *Annu Rev. Biochem* 1995; 64:315-343
48. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. *Lipid Technologies and Applications*.
49. Kent C. Eukaryotic phospholipid biosynthesis. *Annu Rev Biochem* 1995;64:315-343.
50. Zierenberg O, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. *J Lipid Res* 1982;23:1136-1142

51. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. *Altern Med Rev* 1996;1: 148-167.
52. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. *Altern Med Rev* 1996;1:258-274.
53. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. *FASEB* 1991;5:2093-2098.
54. Wurtman RJ , Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. *Lancet* 1977;ii: 68-69.
55. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. *Hepatology* 1995;22:1399-1403.
56. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. *Clin Res* 1968;16:450.
57. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. *Lancet* 1975;ii: 1124-1126.
58. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. *Early Human Dev* 1999;54:157-168.
59. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. *Scand J Gastroenterol* 1993;28:89-94.
60. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. *Med Welt* 1985;72:517-521.
61. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. *Gastroenterology* 1992;102:1363-1370.
62. Panos MZ, Polson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp\*lipid Research (EPL). Bingin-Rhein, Germany: wbn-Verlag; 1990: 103-110.
63. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. *Liver* 1982;2:77- 81
64. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. *La Clinica Terapeutica* 1985;114:183-188
65. Ilic V, Hegic-Janev A. Therapy for HHsAg -positive chronically active hepatitis. *MedWelt* 1991;42:523-525.
66. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo-controlled trial. *Hepatogastroenterol* 1998;45:797-804
67. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? *Alcoholism Clin Exp Res* 1994;18:1286-1288.
68. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. *Drugs* 1996;51:226-;237.
69. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non-steroidal anti-I inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). *Eur J Pharmacol*1985;117: 35-42.
70. Swarm RA, Ashley SW, Soybel DI, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. *Am J Surg* 1987;153:48-53.
71. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. *Pediatr Res* 1998;44:491-495.
72. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.

73. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. *J Neurol Neurosurg Psychiatr* 1985;48:736-742.
74. Esslinger F. Death cap mushroom poisoning: report of clinical experience. *Med Welt* 1966;19:1057-1063.
75. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. *Nutr Rev.* 1994; 52:327-339.
76. Canty DJ, Zeisel SH. Lecithin and choline in human health and disease. *Nutr Rev.* 1994; 52:327-339.
77. Gelenberg AJ, Dorer DJ, Wojcik JD, et al. A crossover study of lecithin treatment of tardive dyskinesia. *Clin Psychiatry.* 1990; 51:149-153.
78. Growdon JH, Gelenberg AJ, Doller J, et al. Lecithin can suppress tardive dyskinesia. *N Engl JMed.* 1978; 298:1029-1030.
79. Hanin I, Ansell GB, eds. *Lecithin. Technological, Biological and Therapeutic Aspects.* New York and London: Plenum Press; 1987.
80. Hanin I, Ansell GB, eds. *Lecithin. Technological, Biological and Therapeutic Aspects.* New York and London: Plenum Press; 1987.
81. Jenkins PJ, Portmann BP, Eddleston AL, Williams R. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. *Liver.* 1982; 2:7-81.
82. KLEMM J, PABST HW. Untersuchungen to uber den Einfluss to therapeutischer Teilkoerperbestrahlungen auf die Leberfunktion und die Schutzwirkung to essentieller Phospholipide. *Strahlentherapie* 1964;123:438-450. [In German, summary in English]
83. KNUECHEL F. Double blind study in patients with alcohol-toxic fatty to liver. *Med Welt* 1979;30:411-416.
84. KOSINA F, BUDKA K, KOLOUCH Z, et al. Viral Essential cholinephospholipids in the treatment of hepatitis. *Cas Lek Ces* 1981;120:957-960.
85. KUNTZ HD, RAUSCH V, BAMMER And "essential" Hepatotoxicity of rifampicin and the effect thereon of choline phospholipids. *Med Welt* 1978;29:452-454.
86. MUETING D, DOHN P, REIKOWSKI J. essential Effect of high doses of phospholipids administered intravenously and perorally on metabolism of albumin and fats and on enzymatic activity of chronically ill to liver patients. *Verhandlungen der Deutsche Gesselchaft fur Innere Medizin* 1972;17:1389-1392.
87. PANOZ MZ, POLSON R, JOHNSON R, ET AL. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic activates hepatitis hepatitis and in acute alcoholic. In: Gundermann K, Schumacher R, eds. *50th Anniversary of Phospholipid Research (EPL) International Symposium.* Bingen/Rhein: wbn-Verlag; 1990.
88. SCHULLER PEREZ, SAN MARTIN F.G. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the marries of alcoholic to liver steatosis. *Med Welt* 1985;72:517-521.
89. SIMONSSON P, NILSSON, AKESSON B Postprandial effects of dietary phosphatidylcholine on plasma lipoproteins in man. *Am J Clin Nutr* 1982 Jan;35(1):36-41
90. SORRENTINO F, DIENE G, CORVAJA and, et al. Polyunsaturated uses of phosphatidylcholine (EPL) in association with vitamin B complex in to liver therapy. *La Clinica Terapeutica* 1982;102:163-183.
91. VISCO G. Polyunsaturated phosphatidylcholine associated with vitamin B complex in the treatment of acute viral hepatitis B. *La Clinica Terapeutica* 1985;114:183-188.
92. WALLNOEFER H, HANUSCH M. "Essential" phospholipids in the treatment of hepatic disease. *Med Monatsschrift* 1973;27:131-136.
93. YANO M, KOGA M, SHIRAHAMA S, et al. Blind assessment of liver biopsy findings in chronic hepatitis: drug efficacy trial of polyene phosphatidylcholine. *Shindan to chiryo* 1978;9:1783-1789.

94. MEL'CHINSKAIA EN, GROMNATSKII NI, KIRICHENKO LL [ lipostabil Hypolipidemic effects of alisat and in patients with diabetes mellitus]. To have Arkh 2000;72(8):57-8 [Article in Russian, with summary in English]
95. ZEMAN M, ZAK A, STOLBA P [The effect of polyene phosphatidylcholine administration on lipid metabolism and glucose tolerance in patients with hyperlipoproteinemia IIB]. Sb Lek 1995;96(1):43-8.
96. WAREMBOURG H, JAILLARD J. Experimentation clinique du lipostabil dans le traitement des angiopathies diabetiques. Lille Med 1968; XIII (suppl):721-3.

## Reference list 2

---

1. [www.lipidlibrary.co.uk/Lipids/pe/index.htm](http://www.lipidlibrary.co.uk/Lipids/pe/index.htm)
2. Kidd PM. Dietary phospholipids as anti-aging nutraceuticals. In: Klatz RA, Goldman R, eds. Anti-Aging Medical Therapeutics. Chicago, IL: Health Quest Publications; 2000: 283-301.
3. Zeisel SH, Blusztajn JK. Choline and human nutrition. Annu Rev Nutr 1994; 14: 269-296.
4. Brook, JG, Linn, S, and Aviram, M. Biochem Med Metabol Biol. 35;31-39, 1986.
5. Canty, DJ and Zeisel, SH. Nutr Reviews. 52;327-339, 1994;
6. Zeisel, SH, et al. Faseb J Nutr Reviews 5;2093-2098, 1991
7. [www.woodmed.com/Phos%20Choline.htm](http://www.woodmed.com/Phos%20Choline.htm)
8. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. Lipid Technologies and Applications. New York, NY: Marcel Dekker; 1997:15-30.
9. Kent C. Eukaryotic phospholipid biosynthesis. Annu Rev Biochem 1995; 64: 315-343.
10. Zierenberg O, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res 1982;23:1136-1142.
11. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. Altern Med Rev 1996;1:148-167.
12. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. Altern Med Rev 1996;1:258-274.
13. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. FASEB 1991;5:2093-2098.
14. Wurtman RJ, Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. Lancet 1977;ii: 68-69.
15. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology 1995;22:1399-1403.
16. Ghyczy M, Boros M. Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. Brit J Nutr 2001;85:409-414.
17. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. Clin Res 1968;16:450.
18. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. Lancet 1975;ii: 1124-1126.
19. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. Early Human Dev 1999;54:157-168.
20. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. Scand J Gastroenterol 1993;28:89-94.
21. Lieber CS, Leo MA. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcoholism Clin Exp Res 1997;21:375-379.
22. Knuchel F. Double blind study in patients with alcohol-toxic fatty liver. Med Welt 1979;30:411-416.

23. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. *Med Welt* 1985;72:517-521.
24. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. *Gastroenterology* 1992;102:1363-1370.
25. Panos MZ, Polson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp\*lipid Research (EPL). Bingin-Rhein, Germany: wbn-Verlag; 1990: 103-110.
26. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. *Gastroenterology* 1994;106:152-159.
27. Marpaung H, Tarigan P, Zein LH, et al. Tuberkulostatische kombinations therapie aus INH, RMP und EMH. *Therapiewoche* 1988;38:734- 740.
28. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. *Liver* 1982;2:77- 81.
29. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. *La Clinica Terapeutica* 1985;114:183-188.
30. Ilic V, Hegic-Janev A. Therapy for HHsAg-positive chronically active hepatitis. *MedWelt* 1991;42:523-525.
31. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo-controlled trial. *Hepatogastroenterol* 1998;45:797-804.
32. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? *Alcoholism Clin Exp Res* 1994;18:1286-1288.
33. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. *Drugs* 1996;51 :226-;237.
34. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non- steroidal anti-inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). *Eur J Pharmacol*1985;117: 35-42.
35. Swarm RA, Ashley SW, Soybel DI, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. *Am J Surg* 1987;153:48-53.
36. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. *Pediatr Res* 1998;44:491-495.
37. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.
38. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high- dose lecithin in Alzheimer's disease. *J Neurol Neurosurg Psychiatr* 1985;48:736-742.
39. Esslinger F. Death cap mushroom poisoning: report of clinical experience. *Med Welt* 1966;19:1057-1063.
40. Kidd PM. Dietary phospholipids as anti-aging nutraceuticals. In: Klatz RA, Goldman R, eds. *Anti-Aging Medical Therapeutics*. Chicago, IL: Health Quest Publications; 2000:283-301.
41. Zeisel SH, Blusztajn JK. Choline and human nutrition. *Annu Rev Nutr* 1994;14:269-296.
42. Schneider M. Phospholipids. In: Gunstone FD, Padley FB, eds. *Lipid Technologies and Applications*. New York, NY: Marcel Dekker; 1997:15-30.
43. Kent C. Eukaryotic phospholipid biosynthesis. *Annu Rev Biochem* 1995;64:315-343.
44. Zierenberg O, Grundy SM. Intestinal absorption of polyenephosphatidylcholine in man. *J Lipid Res* 1982;23:1136-1142.
45. Kidd PM. Cell membranes, endothelia, and atherosclerosis -the importance of dietary fatty acid balance. *Altern Med Rev* 1996;1:148-167.
46. Kidd PM. Phosphatidylcholine, a superior protectant against liver damage. *Altern Med Rev* 1996;1:258-274.

47. Zeisel SH, Da Costa K, Franklin PD, et al. Choline, an essential nutrient for humans. *FASEB* 1991;5:2093-2098.
48. Wurtman RJ, Hirsch MI, Growdon JH. Lecithin consumption raises serum free choline levels. *Lancet* 1977;ii: 68-69.
49. Buchman AL, Dubin MD, Moukarzel AA, et al. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. *Hepatology* 1995;22:1399-1403.
50. Ghyczy M, Boros M. Electrophilic methyl groups present in the diet ameliorate pathological states induced by reductive and oxidative stress: a hypothesis. *Brit J Nutr* 2001;85:409-414.
51. Thistle JL, Schoenfield LJ. Bile acid, lecithin, and cholesterol in repeated human duodenal biliary drainage: effect of lecithin feeding. *Clin Res* 1968;16:450.
52. Toouli J, Jablonski P, Watts JM. Gallstone dissolution in man using cholic acid and lecithin. *Lancet* 1975;ii: 1124-1126.
53. Lloyd J, Todd DA, John E. Serial phospholipid analysis in pre term infants: comparison of Exosurf and Survanta. *Early Human Dev* 1999;54:157-168.
54. Dunjic BS, Axelson J. Gastroprotective capability of exogenous phosphatidylcholine in experimentally induced chronic gastric ulcers in rats. *Scand J Gastroenterol* 1993;28:89-94.
55. Lieber CS, Leo MA. Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. *Alcoholism Clin Exp Res* 1997;21:375-379.
56. Knuchel F. Double blind study in patients with alcohol-toxic fatty liver. *Med Welt* 1979;30:411-416.
57. Schuller-Perez A, San Martin FG. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. *Med Welt* 1985;72:517-521.
58. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. *Gastroenterology* 1992;102:1363-1370.
59. Panos MZ, Polson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann KJ, SchQmacher R, eds. 50th Anniversary of Phosp\*lipid Research (EPL). Bingin-Rhein, Germany: wbn-Verlag; 1990: 103-110.
60. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. *Gastroenterology* 1994;106:152-159.
61. Marpaung H, Tarigan P, Zein LH, et al. Tuberkulostatische kombinations therapie aus INH, RMP und EMH. *Therapiewoche* 1988;38:734-740.
62. Jenkins PJ, Portmann HP. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. *Liver* 1982;2:77-81.
63. Visco G. Polyunsaturated phosphatidylcholine (EPL) associated with vitamin H-complex in the treatment of acute viral hepatitis-H. *La Clinica Terapeutica* 1985;114:183-188.
64. Ilic V, Hegic-Janev A. Therapy for HsAg-positive chronically active hepatitis. *MedWelt* 1991;42:523-525.
65. Niederau C, Strohmeyer G, Heintges T, et al. Polyunsaturated phosphatidylcholine and interferon alpha for treatment of chronic hepatitis H and C: a multicenter, double-blind, placebo-controlled trial. *Hepatogastroenterol* 1998;45:797-804.
66. Schenker S. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? *Alcoholism Clin Exp Res* 1994;18:1286-1288.
67. Halliday HL. Natural vs synthetic surfactants in neonatal respiratory distress syndrome. *Drugs* 1996;51:226-237.
68. Leyck S, Dereu N, Etschenberg E, et al. Improvement of the gastric tolerance of non-steroidal anti-inflammatory drugs by polyene phosphatidylcholine (Phospholipon 100). *Eur J Pharmacol* 1985;117:35-42.

69. Swarm RA, Ashley SW, Soybel DI, et al. Protective effect of exogenous phospholipid on aspirin-induced gastric mucosal injury. *Am J Surg* 1987;153:48-53.
70. Carlson SE. Lower incidence of necrotizing enterocolitis in infants fed a preterm formula with egg phospholipids. *Pediatr Res* 1998;44:491-495.
71. Kidd PM. Unpublished analysis. 1998; El Cerrito, California, USA: drkidd@aol.com.
72. Little A, Levy R, Chuaqui-Kidd P, et al. A double-blind, placebo controlled trial of high-dose lecithin in Alzheimer's disease. *J Neurol Neurosurg Psychiatr* 1985;48:736-742.
73. Esslinger F. Death cap mushroom poisoning: report of clinical experience. *Med Welt* 1966;19:1057-1063.
74. Alberts B, Bray D, Lewis L, et al. *Molecular Biology of The Cell*. New York:Garland Publishing;1989.
75. Jones AL. Anatomy of the normal liver. In: Zakim D, Boyer TD, eds. *Hepatology: A Textbook of Liver Disease*. Philadelphia:WB Saunders; 1996:3-32.
76. Kuntz E. Pilot study with polyenylphosphatidylcholine in severe liver insufficiency. *Med Welt* 1989;40:1327-1329.
77. Kidd PM. Liver biotransformation of xenobiotic chemicals, foods, and drugs to free radical oxidants. In: Levine S, Kidd PM. *Antioxidant Adaptation: Its Role in Free Radical Pathology*. San Leandro, California:Biocurrents;1985: 221-281.
78. Fausto N. Hepatic regeneration. In: Zakim D, Boyer TD, eds. *Hepatology: A Textbook of Liver Disease*. Philadelphia:WB Saunders;1996:32-58.
79. Wallnoefer H, Hanusch M. "Essential" phospholipids in the treatment of hepatic disease. *Med Monatsschrift* 1973;27:131-136.
80. Friedman LS, Martin P, Munoz SJ. Liver function tests and the objective evaluation of the patient with liver disease. In: Zakim D, Boyer TD, eds. *Hepatology: A Textbook of Liver Disease*. Philadelphia:WB Saunders;1996:791-833.
81. Sorrentino F, Diene G, Corvaja E, et al. Use of polyunsaturated phosphatidylcholine (EPL) in association with vitamin B complex in liver therapy. *La Clinica Terapeutica* 1982;102:163-183.
82. Lieber CS. Alcohol and the liver:1994 update. *Gastroenterology* 1994;106:1085-1105.
83. Lieber CS. Alcohol-induced liver disease. In: Maddrey WC, ed. *Gastroenterology and Hepatology: The Comprehensive Visual Reference*. Philadelphia: Current Medicine; 1996:9.1-9.21.
84. Knuechel F. Double blind study in patients with alcohol-toxic fatty liver. *Med Welt* 1979;30:411-416.
85. Schuller Perez A, San Martin F.G. Controlled study using multiply-unsaturated phosphatidylcholine in comparison with placebo in the case of alcoholic liver steatosis. *Med Welt* 1985;72:517-521.
86. Buchman AL, Dubin M, Jenden D, et al. Lecithin increases plasma free choline and decreases hepatic steatosis in long-term total parenteral nutrition patients. *Gastroenterology* 1992;102:1363-1370.
87. Panoz MZ, Polson R, Johnson R, et al. Activity of polyunsaturated phosphatidylcholine in HBsAg negative (autoimmune) chronic active hepatitis and in acute alcoholic hepatitis. In: Gundermann K, Schumacher R, eds. *50th Anniversary of Phospholipid Research (EPL) International Symposium*. Bingen/Rhein: wbn-Verlag;1990.
88. Lieber CS ; DeCarli LM ; Mak KM ; Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. *Hepatology* 1990;12:1390-1398.
89. Li J, Kim C, Leo MA, et al. Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. *Hepatology* 1991;15:373-381.
90. Lieber CS, Robins SJ, Li J, et al. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. *Gastroenterology* 1994;106:152-159.
91. Schenker S, Hoyumpa AM. Polyunsaturated lecithin and alcoholic liver disease: a magic bullet? *Alcoholism: Clin Exp Res* 1994;18:1286-1288.

92. Hoyumpa AM, Schenker S. Drugs and the liver. In: Maddrey WC, ed. Gastroenterology and Hepatology: The Comprehensive Visual Reference. Philadelphia: Current Medicine; 1996:6.1-6.22.
93. [www.thorne.com/altmedrev/fulltext/phos1-4.htm](http://www.thorne.com/altmedrev/fulltext/phos1-4.htm) (21 of 24)26/04/2005 11:28:54  
Phosphatidylcholine
94. Marpaung B, Tarigan P, Zein LH, et al. Tuberkulostatische Kombinations-Ntherapie aus INH, RMP und EMB. Therapiewoche 1988; 38: 734-740.
95. Kuntz HD, Rausch V, Bammer E. Hepatotoxicity of rifampicin and the effect thereon of "essential" choline phospholipids. Med Welt 1978;29:452-454.
96. Hisanaga M, Utsumi S, Miyamoto S, et al. Abnormality of liver function in patients treated with antiepileptic drug and a trial of polyene phosphatidylcholine treatment for these patients. Folia Psychiatr Neurol Japonica 1980;34:318-319.
97. Kuntz E, Neumann-Mangold P. Acute peroral trichloroethylene poisoning. Med Welt 1965;16:2872-2874.
98. Esslinger F. Death cap mushroom poisoning: report of clinical experience. Med Welt 1966;19:1057-1063.
99. Klemm J, Pabst HW. Untersuchungen über den Einfluss therapeutischer Teilkoerperbestrahlungen auf die Leberfunktion und die Schutzwirkung essentieller Phospholipide. Strahlentherapie 1964;123:438-450. [In German, summary in English]
100. Mueting D, Dohn P, Reikowski J. Effect of high doses of essential phospholipids administered intravenously and perorally on metabolism of albumin and fats and on enzymatic activity of chronically ill liver patients. Verhandlungen der Deutsche Gesselchaft für Innere Medizin 1972;17:1389-1392.
101. Hirayama C, Okamura M, Tanikawa K, et al. The clinical effect of polyene phosphatidylcholine in chronic hepatitis in a double-blind test. Rinsho to kenkyu 1978;55:194-198.
102. Yano M, Koga M, Shirahama S, et al. Blind assessment of liver biopsy findings in chronic hepatitis: drug efficacy trial of polyene phosphatidylcholine. Shindan to chiryo 1978;9:1783-1789.
103. Kosina F, Budka K, Kolouch Z, et al. Essential cholinephospholipids in the treatment of viral hepatitis. Cas Lek Ces 1981;120:957-960.
104. Jenkins PJ, Portmann BP, Eddleston ALWF, et al. Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis: results of prospective double-blind controlled trial. Liver 1982;2:77-81.
105. Visco G. Polyunsaturated phosphatidylcholine associated with vitamin B complex in the treatment of acute viral hepatitis B. La Clinica Terapeutica 1985;114:183-188.
106. Hantak I, Boca M, Miculecky M, et al. Essential phospholipids in the treatment of chronic infection with the hepatitis B virus. Vnitri Lekarstvi 1990;36:1164-1171.
107. Fassati P, Horesji J, Fassati M, et al. The effect of choline phospholipids on HBsAg and selected biochemistry tests in cirrhosis of the liver. Cas Lek Ces 1981;120:56-60.
108. Ilic V, Begic-Janev A. Therapy for HBsAg-positive chronically active hepatitis. Effect of "essential" phospholipids. Med Welt 1991;85:523-525.
109. Kalab M, Cervinka J. Essential phospholipids in the treatment of cirrhosis of the liver. Cas Lek Ces 1983;122:266-269. [In Slovak, with English summary]
110. Docker O. Therapy of chronic liver diseases and acute, life-threatening liver failure conditions. Med Welt 1960;20:1079-84.
111. Frosch B, Wagener H. Therapy of hepatitis epidemica. Fortschritte Med 1963;81:725-7.
112. Kautsch E. Comparison of therapy in acute hepatitis epidemica. Med Klinische 1965;60:1401-1410.
113. Rottini E, Bazzanella F, Marri DG, et al. Therapy of different types of liver insufficiency using "Essential" phospholipids. Med Monatsschrift 1963;17:28-30.
114. Wegner H. Essential phospholipids in the therapy of hepatitis infectiosa. Munch Med Welt 1965;5:227-231.
115. Cullis PR. Phospholipids and membrane transport. Can J Biochem 1980; 58, 1091-1095.

116. Hirata F, Axelrod J. Phospholipid methylation and biological signal transmission. *Science* 1980;209:1082-1083.
117. Spector AA, Yorek MA. Membrane lipid composition and cellular function. *J Lipid Res* 1985;26:1015-1035.
118. Shinitzky M. Membrane fluidity and receptor function. In: Kates M, Manson LA, eds. *Membrane Fluidity*. New York: Plenum Press; 1984.
119. Kidd PM. Cell membranes, endothelia, and atherosclerosis—the importance of dietary fatty acid balance. *Alternative Medicine Review* 1996; 1(3): 148-167.
120. Fox JM, et al. Pharmacokinetics of orally ingested phosphatidylcholine. In: Barbeau A, et al, eds. *Nutrition and the Brain, Volume 5*. New York: Raven Press; 1979:95-108.
121. Buzzelli G, Moscarella S, Giusti A, et al. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB 1016) in chronic active hepatitis. *Intl J Clin Pharmacol Ther Toxicol* 1993; 31:456-460.
122. Lieber CS, Leo MA, Mak KM, et al. Choline fails to prevent liver fibrosis in ethanol-fed baboons but causes toxicity. *Hepatology* 1985; 5:561-572.
123. Lipostabil. Natterman International GMBH, 1990;
124. Wojcicki, J, et al. *Phytotherapy Res.* 9;597-599, 1995)
125. Wutman, R, et al. *Nutrition and the Brain*. Vol. 5. Raven Press: New York, 1979; Cohen, B, et al. *Am J Psychiat* 137:242-243, 1980
126. Cohen, B, et al. *Am J Psychiat* 139;1162-1164, 1982.
127. Jope, R, et al. *Am J Psychiat* 142;356-358, 1985
128. Rosenberg, G and Davis, KL. *Am J Clin Nutr.* 36; 709-720, 1982;
129. Levy, R, et al. *Lancet* 1;474-476, 1982;
130. Sitaram, N, et al. *Life Sci* 22;1555-1560, 1978.
131. Daily, JW and Sachan, DS. *J Nutr* 125;1938-1944, 1995
132. Varela-Mreiras, G, et al. *J Nutr Biochem* 3;519-522, 1992.
133. <http://www.gpnotebook.co.uk/simplepage.cfm?ID=-670695364&linkID=34088&cook=yes>
134. Singer, S.J.; Nicolson, G.L. *Science*. 1972, 175, 723-731.
135. <http://rheumatology.oupjournals.org/cgi/content/full/40/3/336>
136. Phosphatidylcholine in the treatment of localized fat. *Journal of Drugs in Dermatology* Oct, 2003; Hexsel D, Serra M, Mazzuco R, Dal'Forno T, Zechmeister D.
137. Adams, J. M. & Cory, S. (2001). Life-or-death decisions by the Bcl-2 protein family. *TIBS* 26: 61-66. *Science Direct*
138. Adrain, C. & Martin, S. J. (2001). The mitochondrial apoptosome: a killer unleashed by the cytochrome seas. *TIBS* 26: 390-397. *Science Direct*
139. Bortner, C. D. & Cidlowski, J. A. (2002). Cellular Mechanisms for the repression of apoptosis. *Annu. Rev. Pharmacol. Toxicol.* 42: 259-281. *PubMed*
140. Cory, S. & Adams, J. M. (2002). The Bcl2 family: Regulators of the cellular life-or-death switch. *Nature Reviews Cancer* 2: 647-656. *PubMed*
141. Curtin, J. F. & Cotter, T. G. (2003). Live and let die: regulatory mechanisms in Fas-mediated apoptosis. *Cellular Signalling* 15: 983-992. *Science Direct*
142. Desagher, S. & Martinou, J.-C. (2000). Mitochondria as the central control point of apoptosis. *Trends in Cell Biology* 10:369-377. *Science Direct*
143. Dumont, E. A. et al. (2001). Real time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart. *Nature Medicine* 7: 1352-1355. *PubMed*
144. Franke, T. F. (2002). Survival signalling by phosphorylation: PI3K/Akt sets the stage. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 235-261. Oxford University Press. OUP

145. Gervais, F. G. et al. (2002). Recruitment and activation of caspase-8 by the Huntingtin-interacting protein Hip-1 and a novel partner Hipp1. *Nature Cell Biology* 4: 95-105. PubMed
146. Gill, C. et al. (2002). Losing heart: the role of apoptosis in heart disease - a novel therapeutic target? *FASEB J* 16: 135-146. PubMed
147. Gottlieb, R. A. & Kitsis, R. N. (2001). Seeing death in the living. *Nature Medicine* 7: 1277-1278. PubMed
148. Hengartner, M. O. (2000). The biochemistry of apoptosis. *Nature* 407: 770-776. PubMed
149. Huang, P. & Oliff, A. (2001). Signaling pathways in apoptosis as potential targets for cancer therapy. *Trends in Cell Biology* 11: 343-348. Science Direct
150. Igney, F. H. & Krammer, P. H. (2002). Death and anti-death: tumour resistance to apoptosis. *Nature Reviews Cancer* 2: 277-288. PubMed
151. Jacobson, M. D. & Bergeron, L. (2002). Cell death in the nervous system. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 278-300. Oxford University Press. OUP
152. Kauffmann, S. H. & Hengartner, M. O. (2001). Programmed cell death: alive and well in the new millennium. *Trends in Cell Biology* 11: 526-534. Science Direct
153. Krammer, P. H. (2000). CD95's deadly mission in the immune system. *Nature* 407: 789-795. PubMed
154. Lam, M. et al. (2001). Photodynamic therapy-induced apoptosis in epidermoid carcinoma cells. *J. Biol. Chem.* 276: 47379-47386. PubMed
155. McCarthy, N. & Bennett, M. R. (2002). Death signalling by the CD95/TNFR family of death domain-containing receptors. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 200-234. Oxford University Press. OUP
156. Nicholson, D. W. (2000). From bench to clinic with apoptosis-based therapeutic agents. *Nature* 407: 810-816. PubMed
157. Pope, R. M (2002). Apoptosis as a therapeutic tool in rheumatoid arthritis. *Nature Reviews Immunology* 2: 1-9. Nature
158. Roy, N. & Cardone, M. H. (2002). The caspases: consequential cleavage. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 93-135. Oxford University Press. OUP
159. Strasser, A. et al. (2000). Apoptosis signaling. *Annu. Rev. Biochem.* 69: 217-245. PubMed
160. Tentori, L. et al. (2002). Potential clinical applications of Poly (ADP-Ribose) Polymerase (PARP) inhibitors. *Pharmacological Research* 45: 73-85. Science Direct
161. Tsujimoto, Y. (2002). Regulation of apoptosis by the Bcl-2 family of proteins. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 136-160. Oxford University Press. OUP
162. Vousden, K. H. & Lu, X. (2002). Live or let die: the cell's response to p53. *Nature Reviews Cancer* 2: 594-604. PubMed
163. Xue, D et al. (2002). Programmed cell death in *C. elegans*: the genetic framework. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 23-55. Oxford University Press. OUP
164. Yu et al. (2002). Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. *Science* 297: 259-263. PubMed
165. Yuan, J. & Yankner, B. A. (2000). Apoptosis in the nervous system. *Nature* 407: 802-809. PubMed
166. Zamzami, N. et al. (2002). Mitochondria in apoptosis: Pandora's box. In *Apoptosis: the molecular biology of programmed cell death* ed. Jacobson, M. D. & McCarthy, N. pp 161-175. Oxford University Press. OUP